Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.

Annals of hematology - 1 Feb 2020

Zhang Xiang, Li Jianhu, Jin Jie, Yu Wenjuan

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Combined Modality Therapy
Share to Cytarabine
Share to Granulocyte Colony-Stimulating Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Share to Remission Induction

Share to Salvage Therapy

Share to Sulfonamides

Source

Identifiers

PMID: 31879788
DOI: 10.1007/s00277-019-03902-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.PMID 31879788Read ↗

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.Semantic proximity Read ↗

Short Course Venetoclax with standard chemotherapy is effective in Early T cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Relapsed/Refractory ETP‐ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell TransplantSemantic proximity Read ↗

Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.Semantic proximity Read ↗

Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.Semantic proximity Read ↗

Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.Semantic proximity Read ↗

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.